Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Drugs In Clinical Trials

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Drug: Galantamine
Clinical Trial ID: NCT00176423
Mode of action: AChE-inhibitor, nAChR modulator
Phase: POC Failed
Note: Add-on for cognitive deficiency shows very moderate effects on negative symptoms but not on cognition

Useful Links:

Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball MP, Buchanan RW. The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol. 2009 Mar-Apr;32(2):69-74. Abstract

Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) . 2004 Jun 1 ; 174(1):45-53. Abstract

July 31, 2016
SRF News
SRF Comments
Text Size
Reset Text Size

Check out our most recent webinar, Studying Psychosis in 22q11 Deletion Syndrome.

See our webinar, The Baby and the Bathwater: Signal and Noise in Psychiatric Neuroimaging.
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright